The introduction of anti-tumor necrosis factor (TNF) alpha agents has significantly transformed the prognosis for patients with inflammatory bowel disease (IBD), resulting in higher remission rates and an enhanced quality of life [17,18]. The gene discussed is TNF; the disease is inflammatory bowel disease.